Efficacy and safety of abrocitinib monotherapy in adolescents and adults: a post hoc analysis of the phase 3 JAK1 atopic dermatitis efficacy and safety (JADE) REGIMEN clinical trial

Background Differences in atopic dermatitis (AD) disease course and manifestation with age may extend to treatment response. Objective To evaluate response maintenance with continuous-/reduced-dose abrocitinib or withdrawal and response to treatment reintroduction after flare in adolescent and adult...

Full description

Saved in:
Bibliographic Details
Main Authors: Carsten Flohr (Author), Michael J. Cork (Author), Michael R. Ardern-Jones (Author), Lawrence F. Eichenfield (Author), Sébastien Barbarot (Author), Claire Feeney (Author), Ricardo Rojo (Author), Irina Lazariciu (Author), John Nesnas (Author)
Format: Book
Published: Taylor & Francis Group, 2023-12-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items